Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1995-6-23
pubmed:abstractText
The clearance of sulphamethoxazole (SMX), a compound metabolised primarily by the N-acetyltransferase NAT1, is increased in cystic fibrosis (CF) patients. We assessed the activity and kinetic properties of NAT1 in lysates of peripheral blood mononuclear leukocytes (MNL) from CF (n = 17) and control (n = 22) subjects using SMX and p-aminobenzoic acid (PABA) as test substrates. The Km and Vmax values of both substrates in MNL from CF patients and control subjects were not significantly different. The acetylation of PABA (100 microM) by intact MNL from CF patients (n = 4) was not different from the observed in intact MNL from controls (n = 9) (25 +/- 3 pmol h-1 per 10(6) MNL vs 27 +/- 4 pmol h-1 per 10(6) MNL). These results suggest that there are not systemic changes in this enzyme in CF. The increased metabolic clearance of SMX may therefore be related to factors other than alterations in the level of activity of the N-acetyltransferase NAT1.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-1587066, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-1717947, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-1752114, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-1762071, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-1914381, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-1996083, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-2015729, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-2246703, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-2312737, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-2338369, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-2340091, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-3046811, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-3293970, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-3606051, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-3698457, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-3875462, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-3895605, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-5514974, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-6607329, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-8097948, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-8162669, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-8375124, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-8431626, http://linkedlifedata.com/resource/pubmed/commentcorrection/7756106-8466547
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
85-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients.
pubmed:affiliation
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't